EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 1, 2002, Pages 59-71

  Kitamura, Tadaichi ^a   Nishimatsu, Hiroaki ^a   Hamamoto, Toshiaki ^a   Tomita, Kyoichi ^a   Takeuchi, Takumi ^a   Ohta, Nobutaka ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Advanced prostate cancer; Carboplatin; Docetaxel; Estramustine phosphate; Estramustine based chemotherapy; Etoposide; Hormone refractory prostate cancer; Interference with cellular microtubule dynamics; Low dose estramustine monotherapy; Paclitaxel

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DIPHENHYDRAMINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FAMOTIDINE; GONADORELIN AGONIST; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; NAVELBINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; UFT; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; WARFARIN;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CAPSULE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; HEART ARREST; HEMORRHAGIC CYSTITIS; HOSPITAL DEPARTMENT; HUMAN; JAPAN; LIVER DYSFUNCTION; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHLEBITIS; PROSTATE CANCER; RANDOMIZATION; REVIEW; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0036084185     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.1.59     Document Type: Review

References (50)

1. Chemotherapy for hormone refractory prostate cancer
2. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
3. Microtubule associated proteins
4. The present role of estramustine phosphate in advanced prostate cancer
5. Estramustine-based chemotherapy
6. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial
7. Preliminary results of Phase II trial of estramustine and vinblastine for patients with progressive hormone-refractory prostate carcinoma
8. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone-refractory prostate cancer
9. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
10. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer
11. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
12. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer
13. Cyclophosphamide. Chap. 55 Antiproliferative agents and drugs used for immunosuppression, I. Alkylating agent, Section - XIII Chemotherapy of neoplastic diseases
14. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma
15. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer
16. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
17. Oral estramustine and oral etoposide for hormone-refractory prostate cancer
18. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer
19. A Phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
20. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer
21. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma
22. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
23. Phase II randomized trial of weekly paclitaxel (Taxol®) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP)
24. Paclitaxel (P) and estramustine phosphate (EP) in patients with hormone refractory prostate cancer (HRPC). A phase II study
25. Phase II trial of oral estramustine, oral etoposide and iv. paclitaxel in hormone-refractory prostate cancer
26. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer
27. Phase II trial of paclitaxel, estramustine, etoposide and carboplatin (TEEC) in the treatment of hormone refractory prostate cancer
28. Phase I/II study of iv. (IV) estramustine (EMP), paclitaxel and carboplatin (Hi-TEC) in patients with castrate, metastatic prostate cancer
29. Preliminary evaluation of short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer
30. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
31. Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of ALGB 9780
32. Nuclear protein matrix as a target for estramustine-induced cell death
33. Docetaxel (Taxotere); an overview of first line monotherapy
34. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
35. Weekly estramustine (E), taxotere (T) and dexamethasone (D) in patients with hormone refractory prostate cancer (HRPC)
36. Estramustine phosphate in the treatment of advanced prostatic cancer
37. Weekly docetaxel and low-dose estramustine phosphate in hormone refractory prostate cancer: A phase II study
38. Estramustine phosphate compared with diethylstilbestrol: A randomized, double-blind, crossover trial for stage D prostate cancer
39. French multicentre study on the use of estramustine phosphate versus diethylstilbestrol
40. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study
41. Estramustine phosphate in prostate cancer. EORTC experience: Preliminary results of Protocol 30762
42. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
43. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma
44. Impairment of estramustine phosphate absorption by concurrent intake of milk and food
45. Necessity of reevaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer
46. Analysing suvival data from clinical trials and observational studies
47. Clinical study on the treatment of prostatic carcinoma with Estracyt
48. Multicenter randomized clinical trial comparing estracyt mono-therapy with combined androgen blockade therapy (CAB) in the treatment of advanced prostate cancer